A Form 4 filed on August 18, 2026, discloses that Nicholas Donoghoe, Executive Vice President and Chief Business/Strategy Officer of AbbVie Inc. (NYSE:ABBV), exercised stock options and sold common shares on August 14, 2026.

Key Highlights

  • Option exercise: Donoghoe exercised options on 32,710 shares of AbbVie common stock at an exercise price of $79.02 per share on August 14, 2026.
  • Shares sold: 32,710 shares of common stock were disposed of on August 14, 2026, at a price of $250 per share.
  • Post-transaction ownership: Following the exercise, beneficial ownership stood at 107,140 shares directly held; following the sale, it stood at 74,430 shares directly held.
  • Option details: The options were granted under the AbbVie Amended and Restated 2013 Incentive Stock Program, with an expiration date of February 20, 2029, and became exercisable in annual increments beginning February 21, 2020.
  • Exempt transaction: According to the filing, the option exercise was "exempt from Section 16 under Rule 16b-3."
  • Remaining derivative securities: Following the transactions, Donoghoe held 0 options of this grant directly.

Donoghoe Option Exercise and Share Sale Details at AbbVie

According to the Form 4 filing, Nicholas Donoghoe, identified as Executive Vice President and Chief Business/Strategy Officer of AbbVie Inc., reported two transactions in AbbVie common stock ($0.01 par value) on August 14, 2026. The first was a code "M" transaction, reflecting the exercise of an employee stock option covering 32,710 shares at a conversion price of $79.02 per share, which the filing records as an acquisition. This brought his directly held beneficial ownership to 107,140 shares at that point.

The second transaction, coded "S," reflects the disposal of 32,710 shares at a price of $250 per share. Following this sale, the filing reports Donoghoe's direct beneficial ownership at 74,430 shares of AbbVie common stock. The filing notes the options were granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program and became exercisable in annual increments: 10,904 shares on February 21, 2020, 10,903 shares on February 21, 2021, and 10,903 shares on February 21, 2022. The option expiration date is listed as February 20, 2029, and the exercise price was $79.02. The filing states the option exercise was "exempt from Section 16 under Rule 16b-3." The form was signed by T.O. Odutayo as Attorney-in-Fact for Nicholas J. Donoghoe and filed on August 18, 2026.

All ownership reported in the filing is listed as direct. No indirect beneficial ownership was reported in connection with these transactions.

What Was Disclosed

The filing reports an option exercise and same-day share sale by AbbVie's EVP and Chief Business/Strategy Officer on August 14, 2026, covering 32,710 shares each, with resulting direct ownership of 74,430 shares of AbbVie common stock.